Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Cancer Prevention: Vaccination Against Human Papillomaviruses at an Early Age Lowers the Risk of Certain Cancers

European Immunisation Week, running from 23 to 29 April 2023, marks the start of the "Year of Vaccination". The campaign highlights the importance of vaccinations for health protection: missed vaccinations should be made up as soon as possible. One focus of the National Steering Committee on Vaccination (Nationale Lenkungsgruppe Impfen, NaLI) is on vaccination against human papillomaviruses (HPV). Early vaccination plays an important role in highly effective and safe HPV vaccination. The Paul-Ehrlich-Institut as a member of the NaLI supports the campaign.

HPV Vaccine Ampoule held in Hand (Source: Leigh Prather/Shutterstock.com)

Infection with certain types of human papillomaviruses (HPV) can cause cancer in the long run. The prophylactic HPV vaccine, recommended for girls and boys aged 9 to 14 years, effectively protects against the most dangerous types of HPV and can significantly reduce the risk of developing certain forms of cancer caused by HPV. A press release from the National Steering Committee on Vaccination (NaLI) provided more information on HPV and the effectiveness of HPV vaccination.

Updated: 21.04.2023